NCT03373006View on ClinicalTrials.gov

A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

January 30, 2020

Study Completion Date

January 30, 2020

Conditions
Prostate Cancer
Interventions
DRUG

Axumin PET/CT

Synthetic amino acid uptake agent injection followed by imaging

Trial Locations (1)

92210

Desert Medical Imaging, Indian Wells

Sponsors

Lead Sponsor

HALO Diagnostics
All Listed Sponsors
lead

HALO Diagnostics

INDUSTRY

NCT03373006 - A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer | Biotech Hunter | Biotech Hunter